Steroid Nasal Sprays Not Suitable For Rx-to-OTC Switch – Task Force
This article was originally published in The Tan Sheet
Executive Summary
The potential for consumers to overdose on intranasal corticosteroids without physician guidance makes the drug category inappropriate for Rx-to-OTC switch, a recent task force report finds
You may also be interested in...
OTC Allergy Drug Use Increases: A Symptom With Multiple Causes
CHPA says growing use of allergy OTCs from 2009 through 2015 in the US is a sign of more consumers prioritizing self-care over using health care services, but allergy specialists say their patients often have to start with an OTC even when they have a prescription.
OTC Allergy Drug Use Increases: A Symptom With Multiple Causes
CHPA says growing use of allergy OTCs from 2009 through 2015 in the US is a sign of more consumers prioritizing self-care over using health care services, but allergy specialists say their patients often have to start with an OTC even when they have a prescription.
Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review
FDA’s Nonprescription Drugs Advisory Committee will meet July 31 to discuss Sanofi’s application to switch the intranasal corticosteroid Nasacort AQ to OTC sale, to be indicated for relief of hay fever symptoms in adults and children.